Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

We evaluated the anti-tumor activity and safety of erlotinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the mammalian target of rapamycin, among patients with recurrent glioblastoma (GBM) in a phase 2, open-label, single-arm trial....

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Reardon, David A., Desjardins, Annick, Vredenburgh, James J., Gururangan, Sridharan, Friedman, Allan H., Herndon, James E., Marcello, Jennifer, Norfleet, Julie A., McLendon, Roger E., Sampson, John H., Friedman, Henry S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2009
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2844073/
https://ncbi.nlm.nih.gov/pubmed/19562254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-009-9950-0
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia